VIVI Cap: Thermal Pen Protection
The VIVI Cap is a thermal case for insulin pens that prevents temperature-related damage.
tempramed.comCrawled Nov 17, 2026
The VIVI Cap is a thermal case for insulin pens that prevents temperature-related damage.
The VIVI Cap1 uses insulation, heat-absorbing chemicals, and electronics to monitor and control insulin pen temperatures.
Soft fabric interior Small and portable Fits up to 5 VIVI Caps and other supply Lightweight fabric Multiple pockets for organization
VIVI Epi is a patented technology developed for space. The VIVI Epi is a carrying case designed to keep EpiPens at a safe temperature.
Damaged insulin can cause unpredictable blood sugar levels and potential health risks.
Insulin should be refrigerated when unused and can be stored outside for about one month while in use.
Creating easy to use, hassle free solutions that save patients lives by protecting them from damaged medications.
TempraMed protects patients from unsafe medication use after leaving pharmacies or hospitals.
Product Patent VIVI CAP1 and VIVI CAP US 10,973,996 & other Pat. Pending VIVI EPI US 10,973,996 & other Pat. Pending
More than 25 years of experience in bringing new products to market.
Orders ship within 1–3 business days, with delivery times varying by location.
TempraMed is using patented, unique space technology, VIVI Cap and VIVI Epi provides a solution for keeping medications at their optimal temperatures.
Returns require items to be unused, in original packaging, and accompanied by proof of purchase.
TempraMed secures a U.S. patent for its **VIVI Cap Smart**, a pen-agnostic smart cap technology. The patent expands the company’s global intellectual property portfolio, reinforcing its position in medical device innovation. The product integrates with existing pens to enhance functionality without requiring proprietary hardware.
TempraMed partners with Poole Bay Holdings to distribute **VIVI Epi**, an unspecified medical product, exclusively in the UK. The agreement focuses on expanding access within **school networks** across the country. The collaboration aims to streamline distribution for educational institutions.
TempraMed secures an exclusive distribution deal with SPORTORO in Croatia, Serbia, and Bosnia and Herzegovina. The agreement grants SPORTORO sole rights to distribute TempraMed’s products in these markets. No further details on the products or terms were disclosed in the announcement.
TempraMed raises up to **C$8 million** through a LIFE offering to expand operations globally and meet projected demand. The funding supports scaling initiatives amid anticipated growth in its core markets. The company leverages the capital to strengthen supply chains and fulfillment capabilities.
TempraMed secures a Mexican patent for its latest medical device, the **VIVI Box**, expanding its intellectual property portfolio in the region. The product’s patent approval follows TempraMed’s focus on developing and protecting innovative healthcare solutions. No further technical or commercial details about the device were disclosed in the announcement.
TempraMed integrates its VIVI Cap with **Apple Health** and **Google Fit**, enabling users to track health metrics and outcomes through these platforms. The connectivity expands data accessibility for wearables and fitness tracking. The move supports seamless health monitoring for users relying on these ecosystems.

TempraMed Technologies is a last-mile medication temperature control provider for injectable temperature-sensitive pharmaceuticals.